Gelteq Limited Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.0M
- Price
- $0.5628
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.94%
- Volume
- 21.0K
About
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Quick stats
Shares outstanding10.7M
Computed float5.1M
Float / shares47.8%
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001920092
Websitehttps://www.gelteq.com
AI Summary
AI-generated1/10
majorbullishclinical trial
Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs
Gelteq announced that its first human clinical trial is scheduled to commence next quarter beginning July 1, 2026, marking a transition into the clinical stage for its pharmaceutical program. Concurrently, the company has initiated a veterinary clinical trial for an antiparasitic drug candidate and a preclinical study for a diabetes medication, expanding its pipeline into major chronic disease categories.
To fund these initiatives, the company secured a strategic debt financing facility of up to US$3.5 million, with US$1 million funded at closing and an additional US$2.5 million pending shareholder approval on June 18, 2026. The financing requires no repayments for at least six months, preserving operational flexibility during this commercialization phase.
Operationally, Gelteq validated its manufacturing capabilities by producing a commercial product for a new customer in East Asia and established a Center of Excellence in Guangdong Province, China. The company also completed successful palatability trials with Kemin Industries, confirming its technology's ability to mask bitter ingredients in animal health formulations.
Red flags
- remaining US$2.5 million of debt financing is contingent on shareholder approval